LAPIX Therapeutics

LAPIX is developing novel, orally bioavailable immune system restoration therapies for significant illnesses. #AutoimmuneDisease #ImmuneTolerance #Oncology

[LAPIX Therapeutics @LAPIX_Tx]

We’re pleased to share our new publication in @IJMS_MDPI—a foundational study behind our antigen-agnostic immune tolerance approach, featuring a predecessor to LPX-TI641, now in Phase 1 #ClinicalTrials. Read the article here: https://t.co/FLZEoTDml2

#Autoimmune #Tregs #Tolerance

[LAPIX Therapeutics @LAPIX_Tx]

We’re pleased to share that we have dosed the first patient in the Phase 1b #ClinicalTrial of our investigational candidate for the treatment of #RheumatoidArthritis (RA) and #PsoriaticArthritis (PsA). Read more in our press release: https://t.co/JSErbqRTTk

[LAPIX Therapeutics @LAPIX_Tx]

Today, we shared positive results from our Phase I #ClinicalTrial for the treatment of #AutoimmuneDiseases.

These results allow us to continue to work towards our mission to develop therapies to address unmet patient needs. Read more: https://t.co/j39EYCUAkT

[LAPIX Therapeutics @LAPIX_Tx]

The appointment of our newest board members, Henry A. McKinnell, Ph.D., Anthony Gibney, and Francisco Leon, MD, Ph.D. marks a pivotal moment for LAPIX. Their collective experience and expertise will be invaluable as we move LPX-TI641 towards Phase II: https://t.co/ffnphNJs2s

[LAPIX Therapeutics @LAPIX_Tx]

Today marks an important milestone for LAPIX and those living with #MultipleSclerosis and other autoimmune conditions, as the first human participants have received LPX-TI641 as a part of our Phase I #ClinicalTrial. Read more about this significant update: https://t.co/6MJoHSWo48

[LAPIX Therapeutics @LAPIX_Tx]

The FDA has cleared our IND application to initiate the Phase 1 #ClinicalTrial of LPX-T1641, a first-in-class immune tolerance restoration therapy for the potential treatment of #MultipleSclerosis and #AutoimmuneDiseases.
Read more here: https://t.co/8L5OW0TBYG

[LAPIX Therapeutics @LAPIX_Tx]

The issuance of our patent for our orally administered #ImmuneTolerance restoration therapy marks a significant step towards creating a new patient-centric standard of care for #AutoimmuneDiseases. Learn more about this important milestone here: https://t.co/jND3F94eFL #Tregs

[LAPIX Therapeutics @LAPIX_Tx]

Lapix is excited to present information on our orally bioavailable immune system restoration therapy in development at @CrohnsColitisFn and @IBDCures’ #IBDInnovate2023 on April 26. Learn more about the event here: https://t.co/NHvrnSswv1

[LAPIX Therapeutics @LAPIX_Tx]

We’re excited to be presenting two posters & have a booth focused on our XenoImmune™ platform at this year’s @AAPSComms National Biotechnology Conference, taking place April 23-26. Learn more & register: https://t.co/lJ01WYEUrG #NBC2023

[LAPIX Therapeutics @LAPIX_Tx]

We’re excited to announce that the first patient has been enrolled in our prospective observational biomarker study (NCT05663853), the largest of its kind for patients with relapsing, primary & secondary progressive #MultipleSclerosis: https://t.co/jmF9bbAxDR #MSAwarenessMonth

[LAPIX Therapeutics @LAPIX_Tx]

We’re thrilled to announce the successful completion of a pre-IND meeting with the FDA for our novel oral #ImmuneTolerance restoration small molecule under development for neuro-autoimmune indications. Learn more here: https://t.co/dP41yZylad

#MultipleSclerosis #Autoimmune

[LAPIX Therapeutics @LAPIX_Tx]

Welcome to LAPIX's Twitter page! Stay tuned for future news and updates surrounding our work in developing orally bioavailable immune system restoration therapies for #AutoimmuneDiseases and #Oncology.